Martin Kolb, MD, PhD, professor of medicine at McMaster University, previews key topics to be presented at this year's European Respiratory Society (ERS) Congress.
The European Respiratory Society (ERS) Congress 2024 will address various aspects of applying artificial intelligence into respiratory medicine, and there will be many exciting presentations on this topic for attendees, says Martin Kolb, MD, PhD, professor of medicine at McMaster University.
This transcript was lightly edited.
Transcript
What are you most excited for at this year's ERS Congress?
The ERS Congress is one of the largest, if not the largest, international gatherings of respiratory experts, and it is in Vienna this time. It will cater to a very broad audience, from industry and academia, [as well as] learners and teachers. It’s a prime gathering.
There are a number of very important and hopefully informative sessions on clinical trials, and why some of the recent clinical trials have failed. There are topics on pollution, environmental, and occupational exposures for people who develop idiopathic pulmonary fibrosis, which may make this disease less idiopathic. There will be sessions focused on the relationship between exposures and interstitial lung disease. Of course, a big topic at the ERS Congress is artificial intelligence.
As many of you will know, artificial intelligence is something that you read [about] everywhere nowadays, in every aspect of life, and it's entering respiratory medicine too. I still don't know how to take artificial intelligence and how to apply it to practice. It certainly is a wonderful research tool and will probably be important for guidelines going forward and making prognostic statements about diseases or a cohort of disease patients.
I don't see yet much [of a] role for an individual. I don't think it's something that will enter the true clinical practice other than indirectly, through big picture statements. But it's a big topic, so it will be shown and showcased in interstitial lung disease, infectious disease, and in other disease areas. So, those are all things that are certainly exciting.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More